No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Mathematical modelling and biostatistics firm Physiomics said on Wednesday that it had secured a new contract with long-standing client, Numab Therapeutics.
Physiomics said the project will use PK/PD modelling and simulation approaches to inform understanding and selection of appropriate clinical dosing for a first-in-human study for an antibody in Numab's inflammation pipeline.
The AIM-listed group said work for the project was expected to begin "imminently" and was expected to be completed within the next six months.
Physiomics added that the project represents "another important step" in its ongoing collaboration applying model-informed drug development to support a data-driven approach to drug development and, in this case, first-in-human dose selection.
Chief executive Dr Peter Sargent said: "We're delighted to be deepening our existing relationship with Numab Therapeutics through this new project. Applying our MIDD expertise to support early clinical development aligns perfectly with our mission to help clients make smarter, faster decisions that can help de-risk development and improve outcomes."
As of 1055 BST, Physiomics shares were up 1.51% at 0.47p.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.